Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Multiple myeloma (MM) is characterized by genetic evolution, necessitating advanced diagnostic tools.
• Identifying oncogenic mutations is crucial for tailoring MM treatment strategies.
• Current methods require optimization for rapid detection of actionable mutations.

Purpose of the Study:

• To evaluate a high-throughput genotyping platform for detecting oncogenic mutations in multiple myeloma.
• To assess the feasibility of using SNaPshot sequencing for mutation analysis in MM patient samples.
• To identify potentially druggable mutations for personalized MM therapy.

Main Methods:

• Development and implementation of a CLIA-approved, high-throughput genotyping platform at Massachusetts General Hospital (MGH).
• DNA extraction from bone marrow and extramedullary plasmacytoma samples from MM patients.
• Sequence analysis using SNaPshot to determine the mutation status of a panel of known oncogenes.

Main Results:

• The SNaPshot platform successfully identified oncogenic mutations in MM patient samples.
• Feasibility of using DNA from both bone marrow and extramedullary tumors was demonstrated.
• Detection of potentially targetable mutations indicates the platform's clinical utility.

Conclusions:

• A CLIA-approved, high-throughput genotyping platform enables rapid detection of targetable mutations in multiple myeloma.
• SNaPshot sequencing is a feasible method for analyzing MM patient DNA, including from extramedullary sites.
• Screening for somatic mutations can reveal novel therapeutic targets, advancing personalized medicine for MM.